Legend Biotech appoints former Novartis exec Ingrid Zhang as CEO amid falling share price

Legend Biotech announced the appointment of Ingrid Zhang, a former Novartis executive, as its new chief executive officer.

The leadership change comes as the company faces growing competition for its CAR‑T therapy Carvykti and a sharp decline in its stock, which has fallen roughly 50%.

Zhang is expected to steer Legend through its next phase, emphasizing product development and market positioning while investors monitor the impact on the company’s performance.